Navigation Links
Butamax™ Responds to Gevo Patent Infringement Lawsuit
Date:4/10/2012

WILMINGTON, Del., April 10, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, commented on the lawsuit filed by Gevo today alleging patent infringement.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"Certain innovative technology is critical for commercial production of isobutanol.  This is especially true for the fundamental biosynthetic pathway claimed in our '188, '889 and related patents filed by Butamax several years ago," said Paul Beckwith, Butamax CEO.  "However, it is our view that the obvious modifications claimed in this recent Gevo patent, reliant on the fundamental pathway, are in fact not critical for our commercialization strategy."

The Butamax patents which are the subject of a lawsuit filed by Butamax against Gevo cover microorganisms which have been engineered to express the required enzymes for isobutanol production, methods of using these microorganisms as well as techniques for recovering isobutanol.  Accordingly, these patents cover fundamental steps for commercial production.  The trial date for the Butamax lawsuit is scheduled for April 2013. 

About Butamax

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.  

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Pam Schools 910-777-7119
pamela.schools@butamax.com


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Responds to Cornelius
2. NeurogesX Responds to EMEAs Day 120 Questions
3. HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
4. Amylin Responds to Eastbourne Letter
5. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
6. Immucor Responds To FDA Notice
7. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
8. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
9. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
10. China Biologic Products Responds to Allegations on Financial Websites
11. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MD (PRWEB) , ... April 27, 2016 , ... ... Greg Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors ... plant pathogen detection. , PathSensors deploys the CANARY® test platform for the ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... system disorders, today announces the appointment of Catherine Moukheibir as ... succeed MedDay,s previous Chairman, Jean Jacques Garaud , who ... The change is effective immediately. Catherine started her ... Boston and London .  She ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office (EPO) today ... three finalists for the European Inventor Award 2016 in the category "Non-European countries." The ... at a ceremony in Lisbon on June 9th. , The human capacity to walk ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):